Compounded Semaglutide After the Shortage: FDA Enforcement and Switch Options

FDA resolved the semaglutide shortage on February 21, 2025. Its temporary shortage-based enforcement-discretion periods ended April 22, 2025 for 503A pharmacies and May 22, 2025 for 503B outsourcing facilities. Those dates ended a broad shortage pathway; they did not create a one-sentence federal ban on every patient-specific compounded prescription. A particular preparation must satisfy the applicable section 503A or 503B and state-law conditions, including restrictions on products that are essentially copies of commercially available drugs.

Quick answer: paths to discuss with your prescriber:

• •Ask whether a patient-specific compounded preparation is appropriate: Enhance MD advertises from $99 for the first month and Shed advertises $299/mo. Availability and price do not establish that a specific prescription satisfies 503A/503B and state-law conditions; see the compounded tirzepatide guide
• •Switch to brand-name Wegovy: NovoCare lists the pen at $199/mo for the first two low-dose fills, then $349/mo at standard strengths ($399 HD), and pill from $149/mo, or as little as $25/mo for eligible commercially insured patients under the savings-card terms. Hers lists pill medication from $149 or pen from $199 plus required $39 first-month/$149 ongoing membership.
• •Switch to brand-name Zepbound: LillyDirect $299/mo starter vial, 20.9% weight loss vs 14.9% for Wegovy. Or telehealth via Sprout Health $199 first month, then $249/mo for brand + compounded options.
• •Try an oral pill: Foundayo (orforglipron) starts at $149/mo at 0.8 mg and rises by dose/refill timing; it requires no injection or fasting. The Wegovy pill starts at $149/mo through NovoCare and may cost as little as $25/mo for eligible commercially insured patients. Compare all oral GLP-1 pills →
• •Ask about a patient-specific semaglutide formulation: Enhance MD advertises from $49 for the first month. Confirm the dispensing pharmacy, exact formulation, legal basis, and ongoing price; 503A pharmacies are state-licensed, not FDA-registered

This guide covers the sourced FDA timeline, product-safety concerns reported by the agency, and public records you can review in our warning and transparency checker. The checker is not an exhaustive FDA database and cannot verify a provider's compliance or certify a medication as safe. For the legal framework, see the brand vs compounded guide.

What Happened: The FDA Crackdown Timeline

The legal status of compounded GLP-1 medications changed significantly over the past 18 months. Here is the timeline of how it unfolded:

The core change is narrower: shortage status had supported temporary enforcement discretion for certain copies under FDA policy. Once FDA resolved the semaglutide shortage, that shortage route and its transition periods ended. Other section 503A or 503B conditions still require a fact-specific analysis; the shortage decision alone does not answer every compounding scenario.

Is Any Compounded Semaglutide Still Legal?

The answer depends on the specific prescription, pharmacy, substance, and applicable federal and state rules. Section 503A can apply to patient-specific prescriptions, but it has multiple conditions, including limits on products that are essentially copies of commercially available drugs. A prescriber-documented determination that a compounded version produces a significant difference for an identified patient can be relevant; it is not an automatic exemption from every other requirement.

• •Patient-specific prescription, Section 503A generally requires compounding for an identified individual patient under a valid prescription or the statute's limited anticipatory-compounding conditions.
• •Essentially-a-copy analysis, When a commercially available drug exists, the prescriber should document any patient-specific significant difference rather than relying on a generic claim such as lower price or convenience.
• •All other conditions, Ingredient eligibility, pharmacy practice, labeling, state law, and other statutory conditions still apply. Section 503B uses a separate framework and FDA registration does not approve a compounded product.

FDA's April 30, 2026 proposal concerns the 503B bulk drug substances list and is not yet a final rule. Track sourced regulatory updates at our safety center or read the dedicated 503B proposal guide.

Your 4 Options as a Former Compounded Semaglutide Patient

If you were relying on compounded semaglutide, you have four realistic paths forward. Here is a quick comparison before we detail each:

Option 1: Discuss Compounded Tirzepatide With Your Prescriber

FDA resolved the tirzepatide shortage on October 2, 2024, and shortage-based enforcement discretion ended in early 2025. Services still advertise compounded tirzepatide, but availability through a licensed pharmacy does not establish that a particular preparation meets every 503A or 503B and state-law condition. The SURMOUNT-1 trial studied Eli Lilly's branded tirzepatide product; its weight-loss results do not establish the effectiveness of a compounded formulation.

Compounded tirzepatide through telehealth starts at $99 for the first month all-in (medication + consultation + shipping). Our featured picks for compounded tirzepatide:

For a full comparison, see our compounded tirzepatide guide and cheapest tirzepatide rankings. Before paying any provider, ask for the dispensing pharmacy's legal name, check the applicable state license or 503B registration and inspection record, and confirm the exact formulation and concentration. We do not certify 503A/503B compliance.

Option 2: Brand-Name Wegovy with Manufacturer Savings

Brand Wegovy (semaglutide 2.4mg weekly injection) is FDA-approved and widely available through telehealth providers and traditional pharmacies. The list price is approximately $1,349/month, but several programs significantly reduce that cost:

• •Wegovy Savings Card, If you have commercial insurance that covers Wegovy, the Novo Nordisk savings card reduces your copay to as low as $0/month for the first month and up to $500/month savings. Cannot be used with Medicare, Medicaid, or any government insurance.
• •NovoCare Patient Assistance Program, Free Wegovy for patients at or below 400% of the federal poverty level (approximately $60,000/year for a single person in 2026). Apply at novonordisk-us.com. Income and residency verification required.
• •GoodRx coupons, Reduce out-of-pocket Wegovy cost to $800 to $950/month without insurance. Not ideal long-term, but useful as a bridge while pursuing insurance coverage.
• •Telehealth providers with insurance verification, Several providers in our rankings will verify your insurance coverage and help with prior authorization appeals if you are denied.

If you had insurance coverage for compounded semaglutide through a telehealth provider, note that coverage for brand Wegovy often requires a separate prior authorization. Our insurance lookup tool can help you check your plan's GLP-1 coverage status.

Option 3: Foundayo (Oral Orforglipron), The Pill Alternative

Foundayo (orforglipron) is a newly FDA-approved oral GLP-1 receptor agonist that was approved for chronic weight management in early 2026. Unlike injectable semaglutide or tirzepatide, it is taken once daily as a pill, no compounding, no injections, standard pharmacy dispensing.

• •Phase 3 trial results: 9.4-14.7% weight loss at 36 weeks depending on dose, less than injectable semaglutide or tirzepatide, but meaningful
• •Cost: ~$349/month list price; manufacturer savings programs in development
• •Key advantage: Oral route, no cold storage required, available at standard retail pharmacies
• •Key limitation: Lower weight loss efficacy than injectable GLP-1s; no generic compounded version yet

Read the full analysis in our Foundayo guide 2026 and see how it compares head-to-head in our Foundayo vs Wegovy pill article. Foundayo is a strong choice for patients who prioritized the convenience of compounded semaglutide over raw efficacy.

Option 4: Appeal Your Insurance Denial

If your insurer previously denied GLP-1 coverage, the landscape has changed. As of 2026, most major commercial insurers cover at least one GLP-1 medication for obesity when medical necessity is documented. A strong appeal should include:

• •BMI documentation, A BMI ≥30, or BMI ≥27 with at least one weight-related comorbidity (Type 2 diabetes, hypertension, obstructive sleep apnea, cardiovascular disease)
• •Prior treatment documentation, Evidence of failed attempts with at least one other weight management approach
• •Letter of medical necessity, From your prescribing provider, ideally a physician or NP, documenting clinical need
• •Specific drug requested, Appeal for the specific covered GLP-1 on your formulary; use your insurer's preferred drug if one is listed

Use our insurance lookup tool to check GLP-1 coverage policies by major insurer, or our eligibility checker to see if you meet the criteria insurers typically require.

How to Choose Between Your Options

Your best path depends primarily on your insurance situation and weight loss goals:

Not sure which provider to use? Take our 7-question match quiz, it factors in your budget, insurance status, injection preference, and health goals to recommend the best provider for your situation. Or see all options ranked by price on our cheapest GLP-1 medication guide, or use the cost calculator to see a side-by-side price comparison.

What This Means for Semaglutide vs. Tirzepatide

Post-shortage enforcement has led some telehealth services to promote tirzepatide instead. That commercial shift should not be mistaken for an efficacy conclusion. Head-to-head and pivotal trials compare specific FDA-approved branded products; they do not establish outcomes for compounded formulations. Our semaglutide vs tirzepatide comparison keeps the branded clinical evidence separate from compounded price listings.

Advertised compounded prices differ, but there is no defensible compounded-product 'weight loss ceiling' to divide into those prices. Individual reports do not substitute for product-specific trials. If a prescriber considers a patient-specific compounded formulation, Willow advertises its GLP-1 program at $299/mo; verify the exact drug, ongoing total, dispensing pharmacy, and legal basis before enrolling. See our brand vs compounded GLP-1 guide for the regulatory framework.

Frequently Asked Questions

Is compounded semaglutide completely illegal in 2026?

Is compounded semaglutide completely illegal in 2026?

No blanket statement covers every preparation. FDA resolved the semaglutide shortage and ended temporary shortage-based enforcement discretion in 2025. A patient-specific 503A prescription or a 503B preparation must still satisfy all applicable federal and state conditions; FDA's 2026 503B bulk-list action remains a proposal, not a final universal ban.

Can I still get compounded semaglutide from my telehealth provider?

Can I still get compounded semaglutide from my telehealth provider?

Some telehealth providers still advertise compounded semaglutide. An advertisement does not establish that a particular prescription or batch meets section 503A or 503B and state-law conditions. Ask for the dispensing pharmacy, exact formulation and concentration, patient-specific rationale, and current license or registration record before paying.

How do I know if tirzepatide is right for me after semaglutide?

How do I know if tirzepatide is right for me after semaglutide?

A prior response to one compounded formulation does not predict your response to another. Tirzepatide and semaglutide have different receptor activity, labeled dosing, contraindications, and evidence bases, while compounded products add formulation and concentration uncertainty. A prescriber should reassess your history and the exact proposed product; our eligibility checker is educational and cannot make that clinical decision.

Will compounded tirzepatide also be banned?

Will compounded tirzepatide also be banned?

No final FDA action cited here creates a simple future 'ban' answer. Tirzepatide's shortage was resolved in October 2024 and shortage-based enforcement discretion ended in early 2025. FDA's April 30, 2026 proposal would affect the 503B bulk-list pathway if finalized, but comments closing did not finalize it. FDA's March 3, 2026 announcement of 30 telehealth marketing letters addressed promotional claims, not a blanket product-safety finding. Check our safety center for sourced updates.

What happens to patients on Medicare who can't get compounded semaglutide?

What happens to patients on Medicare who can't get compounded semaglutide?

Medicare Part D traditionally did not cover GLP-1s for weight loss (only for diabetes). The CMS GLP-1 Bridge Demonstration Program, live as of July 1, 2026, provides a path to coverage for Medicare patients. See our Medicare GLP-1 coverage guide for details on the program and eligibility.

Sources